Richard Gaster
QuietNamed in filings at Venbio Global StrategicOn the current fund
- Board seats filed
- 8
- Named on a board
all filings on record
Named in filings at Venbio Global StrategicOn the current fund
all filings on record
last 24 months
from a verified or cited source
| ALUMIS | Biotech & pharma | March 2024 | Samsara Biocapital |
| Entact Bio | Biotech & pharma | January 2024 | None on file |
| Attralus | Not yet classified | August 2021 | Venbio Select |
| Ventyx Biosciences | Not yet classified | February 2021 | None on file |
| Elevation Oncology | Biotech & pharma | November 2020 | Aisling Capital |
| Aeovian Pharmaceuticals | Biotech & pharma | September 2019 | Sofinnova Venture Partners |
| Arrakis Therapeutics | Biotech & pharma | April 2019 | Nextech Viii Carry Scsp |
| Stargazer Pharmaceuticals | Not yet classified | April 2018 | None on file |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Richard Gaster on the board, based on 5 filed seats with a verified or cited source.
3 more filed seats not yet classified, left out of the shares above.